| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 06/21/2000 | EP1009440A1 Method for inhibiting immunostimulatory dna associated responses |
| 06/21/2000 | EP1009426A1 Method for treating a subject suffering from conditions associated with an extracellular zinc sphingomyelinase |
| 06/21/2000 | EP1009425A1 Wound healing |
| 06/21/2000 | EP1009236A1 Evaluation of, delivery of, and use of agents to treat heart disorders |
| 06/21/2000 | EP1009232A1 Methods for treating insulin resistance and identifying patients at risk for the disease |
| 06/21/2000 | EP0825875B1 Therapeutic composition comprising an antigen or an in vivo generator for generating a compound comprising an amino acid sequence |
| 06/21/2000 | DE19916224C1 Synthetic molecule for delivering active ingredient to cell, used e.g. to treat human immune deficiency virus infection, comprises the ingredient linked to VP2 or 3 peptide from polyoma virus |
| 06/21/2000 | CN1257480A Compound, preparation and use for transferring nucleic acids into cells |
| 06/21/2000 | CN1256952A Gene medicine for treating liver cancer and preparation process thereof |
| 06/20/2000 | US6077987 Implanting in a patient isolated cells genetically engineered in vitro to express bioactive molecules selected from the group consisting of bone growth factors, cartilage growth factors, nerve growth factors, and general growth factors |
| 06/20/2000 | US6077835 Administering composition comprising compacted, unaggregated nucleic acid complexes, each complex consisting essentially of a single nucleic molecule encoding a protein and one or more carrier molecules to facilitate their uptake by target cells |
| 06/20/2000 | US6077834 Combining non-viral receptor ligand and cationic lipid ; adding polynucleotide to form molecular mixture; introducing molecular mixture to cell to enhance delivery of polynucleotide to cell |
| 06/20/2000 | US6077833 Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
| 06/20/2000 | US6077709 Nucleotide sequences that prevent the expression of a human polypeptide that prevent apoptosis in tumor cells; anticarcinogenic agents |
| 06/20/2000 | US6077706 Helicobacter pylori proteins useful for vaccines and diagnostics |
| 06/20/2000 | US6077705 An expression vector for the treatment of the alpha antitrypsin mutation; for gene therapy |
| 06/20/2000 | US6077697 Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
| 06/20/2000 | US6077692 Amino acid sequence of polypeptide for use as wound healing agents, antiulcer agents, antidiabetic agents; treatment of inflammatory bowel disease, lung damage, gastrointestinal and oral injury, gut toxicity, skin grafts and disorders |
| 06/20/2000 | US6077685 Tumor suppressor merlin and antibodies thereof |
| 06/20/2000 | US6077675 Drug screening by contacting compound with recombinant cell which expresses a nucleic acid encoding the receptor and monitoring for binding or modulation of receptor; anticonvulsants; analgesics; cognition enhancers |
| 06/20/2000 | US6077663 Composition for introducing nucleic acid complexes into higher eucaryotic cells |
| 06/20/2000 | US6077510 Borna disease viral sequences, diagnostics and therapeutics for nervous system diseases |
| 06/15/2000 | WO2000034780A2 METHODS AND COMPOSITIONS USEFUL FOR TARGETING ACTIVATED VITRONECTIN RECEPTOR αvβ¿3? |
| 06/15/2000 | WO2000034500A2 Methods for increasing the efficiency of gene transfer |
| 06/15/2000 | WO2000034499A1 Use of an immuno complex for the preparation of a therapeutic composition useful for transfecting a polynucleotide into macropinocyte cells |
| 06/15/2000 | WO2000034497A2 Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors |
| 06/15/2000 | WO2000034496A2 Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene |
| 06/15/2000 | WO2000034494A1 A recombinant vector expressing multiple costimulatory molecules and uses thereof |
| 06/15/2000 | WO2000034488A1 Bacterial transcription regulators |
| 06/15/2000 | WO2000034487A1 STREPTOCOCCAL C5a PEPTIDASE VACCINE |
| 06/15/2000 | WO2000034483A2 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 06/15/2000 | WO2000034474A2 Growth factor homolog zvegf3 |
| 06/15/2000 | WO2000034468A2 Muc-1 antagonists and methods of treating immune disorders |
| 06/15/2000 | WO2000034467A1 Cancer cell vaccine |
| 06/15/2000 | WO2000034455A2 Methods and systems useful for transferring genes into pancreatic islets ex vivo and into the pancreas in vivo |
| 06/15/2000 | WO2000034447A2 Human ubiquitin ligase e3 for the modulation of nf-kappa b |
| 06/15/2000 | WO2000034444A2 Method and composition for preserving viruses |
| 06/15/2000 | WO2000034334A1 DNA ENCODING A MAMMALIAN RECEPTOR (fb41a) AND USES THEREOF |
| 06/15/2000 | WO2000034310A1 Purified and isolated serine-threonine kinase receptors associated protein |
| 06/15/2000 | WO2000034308A2 Protein transduction system and methods of use thereof |
| 06/15/2000 | WO2000034303A1 METHODS OF MODULATING TUMOR NECROSIS FACTOR α-INDUCED EXPRESSION OF CELL ADHESION MOLECULES |
| 06/15/2000 | WO2000034294A2 Tumor necrosis factor receptor homologue-1 ('trh1') |
| 06/15/2000 | WO2000033885A1 Supramolecular complexes containing therapeutic agents |
| 06/15/2000 | WO2000033880A2 Conjugate used for enriching in neuronal cells |
| 06/15/2000 | WO2000033872A2 Method of and compositions for immunization with the pseudomonas v antigen |
| 06/15/2000 | WO2000033655A1 Plastin promoter directed gene therapy |
| 06/15/2000 | WO2000015649A9 METHODS OF INHIBITING SMOOTH MUSCLE CELL PROLIFERATION AND PREVENTING RESTENOSIS WITH A VECTOR EXPRESSING RB2/p130 |
| 06/15/2000 | WO2000014234A9 Prostate specific promoter and regulation of gene expression |
| 06/15/2000 | WO2000009711A3 ISOLATED AND PURIFIED HUMAN SOLUBLE GUANYLYLCYCLASE α1/β1 (hsGCα1/β1) |
| 06/15/2000 | WO2000008192A3 Herpesviral vectors for gene delivery |
| 06/15/2000 | WO2000008143A3 Gene isolated on the short arm of human chromosome 17 |
| 06/15/2000 | WO1999066051A3 Nek-related and bub1-related protein kinases |
| 06/15/2000 | WO1999062940A3 Methods of altering cardiac cell phenotype |
| 06/15/2000 | WO1999060021A3 Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system |
| 06/15/2000 | WO1999055858A3 Human nucleic acid sequences obtained from pancreas tumor tissue |
| 06/15/2000 | WO1999055847A3 Enzymatic nucleic acids molecules which modulate the expressions and/or replication of hepatitis c virus |
| 06/15/2000 | WO1999047669A3 Human nucleic acid sequences from tissue of breast tumors |
| 06/15/2000 | WO1999002550A8 Ctl epitopes from ebv |
| 06/15/2000 | WO1998051278A3 High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
| 06/15/2000 | DE19856066A1 A novel metabotropic receptor complex from the central nervous system, related coding sequences and methods of identifying binding substances, ligands and interactions with other proteins |
| 06/15/2000 | DE19856065A1 Rekombinanter, adenoviraler Vektor mit limitierter Autoreplikationsfähigkeit in vivo A recombinant adenoviral vector with limited car capacity for replication in vivo |
| 06/15/2000 | CA2746535A1 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 06/15/2000 | CA2678259A1 A recombinant vector expressing multiple costimulatory molecules and uses thereof |
| 06/15/2000 | CA2354644A1 Muc-1 antagonists and methods of treating immune disorders |
| 06/15/2000 | CA2354612A1 Tumor necrosis factor receptor homologue-1 ("trh1") |
| 06/15/2000 | CA2354232A1 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 06/15/2000 | CA2354188A1 Cancer cell vaccine |
| 06/15/2000 | CA2354044A1 Protein transduction system and methods of use thereof |
| 06/15/2000 | CA2353552A1 Supramolecular complexes containing therapeutic agents |
| 06/15/2000 | CA2351890A1 Method and composition for preserving viruses |
| 06/15/2000 | CA2351641A1 Plastin promoter directed gene therapy |
| 06/15/2000 | CA2351628A1 Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene |
| 06/15/2000 | CA2351452A1 Methods and compositions useful for targeting activated vitronectin receptor .alpha.v.beta.3 |
| 06/15/2000 | CA2349404A1 Use of an immuno complex for the preparation of a therapeutic composition useful for transfecting a polynucleotide into macropinocyte cells |
| 06/14/2000 | EP1008653A2 Recombinant adenoviral vector with limited capability to self-replicate |
| 06/14/2000 | EP1008652A1 Vectors based on recombinant defective viral genomes, and their use in the formulation of vaccines |
| 06/14/2000 | EP1008351A1 Carcinostatic agents |
| 06/14/2000 | EP1007735A1 Anti-sense oligonucleotide pharmacological agents |
| 06/14/2000 | EP1007717A2 Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta |
| 06/14/2000 | EP1007716A1 Use of lentiviral vectors for antigen presentation in dendritic cells |
| 06/14/2000 | EP1007715A2 Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same |
| 06/14/2000 | EP1007714A1 Regulatory sequences capable of conferring expression of a heterologous dna sequence in endothelial cells in vivo and uses thereof |
| 06/14/2000 | EP1007699A1 Peptide-enhanced transfections |
| 06/14/2000 | EP1007697A2 Production of proteins in eggs |
| 06/14/2000 | EP1007693A1 Pak kinase genes and polypeptides and methods of use thereof |
| 06/14/2000 | EP1007687A1 Fiv vaccine |
| 06/14/2000 | EP1007686A1 Tuberculosis vaccine |
| 06/14/2000 | EP1007685A2 Surface exposed proteins from chlamydia pneumoniae |
| 06/14/2000 | EP1007679A1 Recombinant human erythropoietin with advantageous glycosylation profile |
| 06/14/2000 | EP1007678A1 Kringle1 |
| 06/14/2000 | EP1007677A2 Protease-related protein |
| 06/14/2000 | EP1007675A1 Porcine mhc class i genes and uses thereof |
| 06/14/2000 | EP1007673A1 Novel bone mineralization proteins, dna, vectors, expression systems |
| 06/14/2000 | EP1007672A1 Intracellular glucocorticoid-induced leucine zippers modulators of apoptic cell death pathways |
| 06/14/2000 | EP1007671A1 Fanconi-gen ii |
| 06/14/2000 | EP1007664A1 Therapies involving mutated heat shock transcription factor |
| 06/14/2000 | EP1007663A2 Human proteins |
| 06/14/2000 | EP1007662A1 Method for induction of apoptotic cell death in malignant cells, through reduction of the rb to apoptosis inducing proteins ratio |
| 06/14/2000 | EP1007661A2 Secreted proteins and polynucleotides encoding them |
| 06/14/2000 | EP1007658A2 Mdm2-specific antisense oligonucleotides |